Skip to content
AnalystLens

MRNA · Moderna, Inc.

117 filings

8-K

MRNA 8-K Current Reports

Moderna, Inc. - 117 current reports

Filing record · 2018–202610-K910-Q238-K117

MRNA filed 9 annual reports (10-K), 23 quarterly reports (10-Q) and 117 current reports (8-K) between 2018 and 2026.

  1. Material agreement8-K · Aug ’20Aug ’20
  2. Leadership change8-K · Sep ’22Sep ’22
  3. Material agreement8-K · Nov ’25Nov ’25
Showing 1-50 of 117 filings
8-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Sep 30, 2026)

Moderna, Inc. announced a significant leadership change with the appointment of Juan Andres as its new Chief Operating Officer (COO), effective October 5, 2026. This is a newly created role, indicating a strategic move by Moderna to bolster its operational capabilities as it continues to scale and diversify. Mr. Andres is a familiar face, having previously held key roles at Moderna, including Chief Technical Operations and Quality Officer, where he was instrumental in scaling manufacturing for its COVID-19 vaccine. His return and appointment to this critical operational role suggest a focus on reinforcing production, supply chain, and overall business execution.

Sep 30, 20268-K
Material AgreementsFinancial EventsSecurities & Listing+2

Moderna, Inc. 8-K Report, Material Agreement (Sep 1, 2026)

Moderna, Inc. has successfully completed a private offering of $3.0 billion in aggregate principal amount of 0.00% Convertible Senior Notes due 2032. This issuance, which included the full exercise of an over-allotment option for an additional $400 million, was conducted under an indenture with U.S. Bank Trust Company, National Association. The Notes are unsecured general obligations of the company, maturing on March 1, 2032, and do not bear regular interest, though special interest may accrue under specific circumstances. Holders can convert these notes into Moderna's common stock under defined conditions, including specific stock price performance thresholds or if the company undergoes certain events. The initial conversion price is set at approximately $210.58 per share, representing a significant premium to the stock price at the time of the offering, which is intended to mitigate potential dilution.

Sep 1, 20268-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Jul 31, 2026)

Moderna, Inc. has filed an 8-K report on July 31, 2026, to announce its financial results for the second quarter ended June 30, 2026. The primary purpose of this filing is to furnish a press release containing these results, which is incorporated by reference. Investors should note that this information is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act, meaning it does not carry the same liabilities. However, it provides timely insights into Moderna's recent financial performance and operational status for the period. While the specific financial figures are detailed in the furnished press release (Exhibit 99.1), the filing itself serves as the official notification of their disclosure. Investors and analysts will need to refer to the press release for details on revenue, earnings, product sales (particularly related to its mRNA platform and any approved vaccines/therapeutics), research and development expenditures, and forward-looking guidance. This report is crucial for assessing the company's trajectory and its ability to execute on its pipeline and commercial strategies.

Jul 31, 20268-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Jul 8, 2026)

Moderna, Inc. (MRNA) has announced a significant addition to its Board of Directors with the appointment of Michael McDonnell, effective July 8, 2026. Mr. McDonnell brings over 35 years of extensive financial leadership experience, including recent service as Chief Financial Officer at Biogen Inc. and prior CFO roles at IQVIA Holdings Inc., Intelsat S.A., MCG Capital Corporation, and EchoStar Communications. His appointment to the Board as a Class II director and to the Audit Committee is expected to bolster the company's financial oversight and strategic guidance. This move, announced via a press release furnished with the 8-K filing, signals a continued focus on strengthening corporate governance and leveraging seasoned financial expertise. The filing also notes changes to committee memberships, with David Rubenstein moving from the Audit Committee to the Nominating and Corporate Governance Committee.

Jul 8, 20268-K
Shareholder MattersCorporate ChangesExhibits & Filings

Moderna, Inc. 8-K Report, Bylaw Amendment (May 11, 2026)

Moderna, Inc. (MRNA) filed an 8-K on May 11, 2026, detailing key governance changes and outcomes from its 2026 Annual Meeting of Stockholders. The Board of Directors adopted a by-law amendment designating federal district courts as the exclusive forum for Securities Act of 1933 claims, aligning with recent Delaware corporate law changes. This aims to streamline litigation and provide a more predictable legal environment for such disputes. Additionally, the filing reports the results of the Annual Meeting held on May 6, 2026. Stockholders overwhelmingly re-elected the Class II directors, approved executive compensation on an advisory basis, and voted for annual advisory votes on executive compensation. The appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026 was also ratified with strong support. These outcomes reflect continued shareholder confidence in the company's leadership and financial oversight.

May 11, 20268-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (May 1, 2026)

Moderna, Inc. has filed an 8-K report on May 1, 2026, primarily to announce its first-quarter financial results for the period ending March 31, 2026. The report itself does not contain detailed financial figures but instead incorporates by reference a press release (Exhibit 99.1) which holds the specific financial and operational performance data. Investors should refer to this press release for a comprehensive understanding of the company's performance during the first quarter of 2026. This filing serves as a standard notification of material information release. While the 8-K itself is brief, the accompanying press release is crucial for assessing Moderna's revenue, profitability, product pipeline progress, and any forward-looking guidance provided by management. Investors are advised to carefully review the contents of Exhibit 99.1 for insights into the company's financial health and strategic direction.

May 1, 20268-K
Material Agreements

Moderna, Inc. 8-K Report, Material Agreement (Mar 5, 2026)

Moderna, Inc. has entered into a significant settlement agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH to resolve all ongoing patent infringement litigation. This agreement, effective March 3, 2026, provides crucial certainty for Moderna's infectious disease product portfolio, including its key vaccines Spikevax® and mRESVIA®, as well as its future pipeline, by eliminating future royalty obligations. The settlement includes an initial noncontingent payment of $950 million to Arbutus/Genevant, due by July 8, 2026. Furthermore, the agreement outlines a potential additional contingent payment of up to $1.3 billion, which is tied to the outcome of Moderna's appeal to the Court of Appeals for the Federal Circuit. This appeal concerns whether Section 1498 of U.S. Code limits Arbutus/Genevant's claims for infringement on vaccine doses sold to the U.S. Government. If Moderna prevails in its appeal on all relevant doses, this contingent payment will not be due. Conversely, a partial win or an unfavorable ruling could result in a prorated contingent payment. The settlement also grants Moderna a fully paid-up, royalty-free, irrevocable license to utilize lipid SM-102-based lipid nanoparticle (LNP) formulations in its infectious disease vaccines.

Mar 5, 20268-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Feb 13, 2026)

Moderna, Inc. has filed an 8-K report on February 13, 2026, to announce its financial results for the fourth quarter and full year ended December 31, 2025. The report primarily directs investors to a press release furnished as Exhibit 99.1 for the detailed financial performance and operational updates. Investors should refer to this press release for specific figures on revenue, profitability, and any forward-looking statements regarding the company's pipeline and commercial outlook for 2026.

Feb 13, 20268-K
Regulation FDOther EventsExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Feb 11, 2026)

Moderna, Inc. (MRNA) announced via an 8-K filing on February 11, 2026, that it received a Refusal-to-File letter from the U.S. Food and Drug Administration (FDA) for its investigational seasonal influenza vaccine, mRNA-1010. This means the FDA will not initiate a review of the Biologics License Application (BLA) for this vaccine candidate at this time. The company furnished a press release dated February 10, 2026, detailing this development, which is included as an exhibit to the filing. This news represents a significant setback for the mRNA-1010 program and could impact Moderna's influenza vaccine pipeline and competitive positioning in the seasonal flu market. Investors should closely monitor any further communication from Moderna regarding the specific reasons for the FDA's decision and the company's plans for addressing these concerns, including potential resubmission strategies or reallocation of resources.

Feb 11, 20268-K
Earnings & ResultsRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Jan 12, 2026)

Moderna, Inc. (MRNA) filed an 8-K on January 12, 2026, providing preliminary financial updates for the fiscal year ended December 31, 2025, during its presentation at the J.P. Morgan Healthcare Conference. The company anticipates approximately $1.9 billion in revenue for the full year 2025. This revenue figure should be considered in conjunction with expected GAAP operating expenses, which are projected to be in the range of $5.0 billion to $5.2 billion for the same period. Despite the anticipated operating expense levels, Moderna maintains a strong liquidity position, expecting to close the year with approximately $8.1 billion in cash, cash equivalents, and marketable securities as of December 31, 2025. Investors should note that these figures are preliminary and unaudited, and the company's full financial statements for the year are still undergoing audit, which may lead to revisions.

Jan 12, 20268-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Jan 5, 2026)

Moderna, Inc. has filed an 8-K report on January 5, 2026, primarily disclosing a letter sent to its shareholders. This letter, attached as Exhibit 99.1, is intended to provide an update and is being furnished under Regulation FD, meaning it's not considered 'filed' for liability purposes under Section 18 of the Exchange Act. While the specific content of the shareholder letter is not detailed in the 8-K itself, its issuance suggests the company is proactively communicating significant information to its investors. Investors should look to the attached Exhibit 99.1 for the core details of Moderna's communication. Given the typical nature of such letters, it is likely to cover key business developments, strategic updates, or financial performance commentary. The filing serves as an official record of this communication, ensuring transparency and broad dissemination of information to all shareholders.

Jan 5, 20268-K
Material AgreementsFinancial EventsExhibits & Filings

Moderna, Inc. 8-K Report, Material Agreement (Nov 24, 2025)

Moderna, Inc. (MRNA) has announced a significant financing event through a Credit and Guaranty Agreement executed on November 19, 2025, detailed in an 8-K filing dated November 24, 2025. The company has secured a $1.5 billion credit facility, comprising a $600 million initial term loan and $900 million in delayed draw term loans. This facility provides substantial financial flexibility, with a portion of the delayed draw loans contingent upon achieving key regulatory milestones for its late-stage clinical pipeline, underscoring the importance of its drug development progress. The credit facility matures in November 2030 and is guaranteed by several of Moderna's international subsidiaries, secured by an all-asset collateral grant. Key financial covenants include a minimum liquidity requirement, which can be eased if the company's market capitalization exceeds $5 billion, and is subject to an equity cure provision. This financing is crucial for supporting Moderna's ongoing research and development efforts and advancing its pipeline towards commercialization.

Nov 24, 20258-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Nov 20, 2025)

Moderna, Inc. (MRNA) has filed an 8-K report on November 20, 2025, primarily to furnish a press release detailing pipeline progress and business strategy updates presented at their Analyst Day. This filing serves to inform investors about the company's forward-looking initiatives and advancements within its drug development programs. While not deemed "filed" for regulatory liability purposes, the content provides significant insight into Moderna's strategic direction and operational achievements.

Nov 20, 20258-K
Shareholder Matters

Moderna, Inc. 8-K Report, Shareholder Vote Results (Nov 13, 2025)

Moderna, Inc. (MRNA) filed an 8-K on November 13, 2025, reporting the results of its Special Meeting of Shareholders held on November 12, 2025. The primary focus of the meeting was a shareholder vote on a one-time stock option exchange program for its non-Executive Committee employees. This proposal was overwhelmingly approved by stockholders, indicating strong support for management's proposed equity incentive adjustments. Additionally, shareholders approved a proposal to adjourn the meeting if necessary. This adjournment provision grants the company flexibility to continue soliciting votes for the option exchange program, especially if initial voting results were borderline or to ensure maximum participation. The filing confirms a quorum was present and details the voting results for both proposals, with no broker non-votes recorded.

Nov 13, 20258-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Nov 6, 2025)

Moderna, Inc. (MRNA) filed an 8-K on November 6, 2025, to report its third-quarter financial results for the period ended September 30, 2025. The filing primarily serves as a notification of the press release containing these results, which is furnished as Exhibit 99.1. Investors should refer to this press release for detailed financial performance, operational updates, and forward-looking statements related to the company's mRNA pipeline and commercial products. While the 8-K itself is procedural, it signals the release of crucial information regarding Moderna's revenue, earnings, cash position, and progress on key development programs. The furnished press release is the primary source for understanding the company's performance during the third quarter and its outlook for the remainder of the fiscal year. Investors are encouraged to review Exhibit 99.1 for comprehensive insights into Moderna's business operations and financial health.

Nov 6, 20258-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Aug 1, 2025)

Moderna, Inc. (MRNA) has filed an 8-K report on August 1, 2025, to announce its financial results for the second quarter ended June 30, 2025. The primary driver of this filing is the accompanying press release, furnished as Exhibit 99.1, which details the company's performance during the quarter. Investors should note that this information is furnished and not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, meaning it does not carry the same level of regulatory liability as a fully filed document, though it is still critical for understanding the company's operational and financial standing. While the 8-K itself is brief, the press release (Exhibit 99.1) is expected to contain key financial metrics such as revenue, earnings per share, and cash flow, along with qualitative commentary on business developments, pipeline progress, and future outlook. Investors are encouraged to review the press release for specific details regarding sales of existing products, advancements in clinical trials for new therapies, and any strategic partnerships or collaborations. The filing also includes the cover page interactive data file in XBRL format for enhanced data analysis.

Aug 1, 20258-K
Shareholder Matters

Moderna, Inc. 8-K Report, Shareholder Vote Results (May 5, 2025)

Moderna, Inc. (MRNA) has filed an 8-K report detailing the results of its 2025 Annual Meeting of Stockholders held on April 30, 2025. The meeting saw strong support for the election of directors, with all nominated individuals securing a substantial majority of votes. This indicates continued confidence from shareholders in the current leadership and the board's strategic direction. Furthermore, stockholders approved, on an advisory basis, the compensation of the company's named executive officers, demonstrating general agreement with executive pay practices. The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also overwhelmingly ratified. These outcomes suggest a stable governance environment and shareholder alignment on key corporate governance matters.

May 5, 20258-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (May 1, 2025)

Moderna, Inc. (MRNA) filed an 8-K on May 1, 2025, to report its financial results for the first quarter ended March 31, 2025. The filing primarily consists of a press release announcing these results, which is furnished as Exhibit 99.1. Investors should refer to this press release for detailed financial performance, operational updates, and forward-looking statements. While the 8-K itself does not contain the specific financial figures, it serves as the official notification of their release. The furnished press release will contain crucial information regarding revenue, earnings per share, product sales (likely including COVID-19 vaccine performance and any contributions from newer pipelines), research and development expenses, and management's outlook for the remainder of the fiscal year. Investors are advised to review Exhibit 99.1 for a comprehensive understanding of Moderna's Q1 2025 performance and its implications for future growth.

May 1, 20258-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Feb 14, 2025)

Moderna, Inc. (MRNA) has filed an 8-K report on February 14, 2025, primarily furnishing its fourth quarter and full-year financial results for the period ending December 31, 2024, through a press release. While the filing itself is procedural, the accompanying press release (Exhibit 99.1) contains the core financial and operational data crucial for investor assessment. Investors should carefully review this press release for detailed performance metrics, revenue generation, profitability, and any forward-looking guidance provided by the company. The filing serves as the official notification of the release of these results. It's important for investors to note the "furnished" nature of the information, meaning it is not subject to the same liabilities under Section 18 of the Exchange Act as "filed" information, though it can be incorporated by reference into other filings. The key takeaway for investors is to access and analyze the detailed financial information presented in the press release to understand Moderna's performance and outlook.

Feb 14, 20258-K
Earnings & ResultsRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Jan 13, 2025)

Moderna, Inc. (MRNA) filed an 8-K on January 13, 2025, providing preliminary financial insights for the fiscal year ended December 31, 2024. The company announced unaudited product sales in the range of $3.0 billion to $3.1 billion. This indicates a significant revenue stream, though it's crucial to note these figures are preliminary and subject to audit. Furthermore, Moderna anticipates a strong cash position, reporting unaudited cash, cash equivalents, and marketable securities of approximately $9.5 billion as of December 31, 2024. This robust liquidity provides financial flexibility for ongoing research, development, and potential strategic initiatives. Investors should monitor the upcoming audited financial statements for a complete and confirmed picture of the company's performance and financial health.

Jan 13, 20258-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Nov 7, 2024)

Moderna, Inc. (MRNA) has filed an 8-K report on November 7, 2024, to announce its third quarter 2024 financial results. The primary driver of this filing is the accompanying press release, which contains the detailed financial performance for the period ending September 30, 2024. Investors should refer to the furnished press release (Exhibit 99.1) for specific figures related to revenue, earnings, and other key financial metrics. This report does not involve material events beyond the standard quarterly earnings announcement, but it serves as the official notification and public dissemination of the company's recent financial standing.

Nov 7, 20248-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Oct 2, 2024)

Moderna, Inc. (MRNA) announced a change to its Board of Directors through an 8-K filing on October 2, 2024. The key development is the appointment of Abbas Hussain as a new director, effective October 2, 2024. Mr. Hussain brings significant experience in the healthcare sector, having previously served as CEO of Vifor Pharma and holding various leadership roles at GlaxoSmithKline and Eli Lilly and Company. His appointment increases the Board size to nine directors, and he will serve as a Class II director until the 2026 annual meeting. Furthermore, Mr. Hussain has been appointed to the Board's Audit Committee. This addition to the Board signifies a strengthening of Moderna's governance and oversight, particularly within its audit functions, by leveraging Mr. Hussain's extensive industry leadership and operational background. Investors should note that his compensation will align with the company's established non-employee director compensation policy, and he has entered into standard indemnification agreements. There are no disclosed related-party transactions or disqualifying arrangements associated with his appointment.

Oct 2, 20248-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Sep 12, 2024)

Moderna, Inc. (MRNA) filed an 8-K on September 12, 2024, primarily to furnish a press release regarding its research and development (R&D) and business updates. This press release was issued in conjunction with an investor event held on the same date. While the 8-K itself contains minimal new information, it serves to disseminate key updates from the investor event to the public, which is crucial for transparency and informing investors about the company's progress and strategic direction. Investors should refer to the furnished press release (Exhibit 99.1) for the substantive details of these updates.

Sep 12, 20248-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Aug 1, 2024)

Moderna, Inc. (MRNA) announced its second quarter financial results for the period ended June 30, 2024, via a press release filed on August 1, 2024. This 8-K filing primarily serves to furnish this press release, which contains the company's operational and financial performance for the quarter. Investors should refer to the furnished press release (Exhibit 99.1) for the detailed financial results, including revenue, profitability, and any forward-looking statements or guidance.

Aug 1, 20248-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Jul 23, 2024)

Moderna, Inc. has announced significant changes to its Board of Directors, effective August 5, 2024. Long-standing board members Robert Langer and Stephen Berenson will resign from their positions but will transition to consulting roles. This move will allow their outstanding equity awards to continue vesting. Concurrently, the company has appointed David M. Rubenstein, Co-Founder and Co-Chairman of The Carlyle Group, to the Board. Mr. Rubenstein will fill the vacancy left by Mr. Berenson on the Audit Committee and will serve as a Class III director. These changes will result in the Board size being fixed at eight directors.

Jul 23, 20248-K
Shareholder MattersCorporate ChangesExhibits & Filings

Moderna, Inc. 8-K Report, Bylaw Amendment (May 9, 2024)

Moderna, Inc. (MRNA) filed an 8-K on May 9, 2024, reporting on key outcomes from its 2024 Annual Meeting of Stockholders held on May 6, 2024. The most significant investor-focused development is the stockholder approval of two amendments to the Company's Certificate of Incorporation. The first amendment grants shareholders holding no less than 20% of outstanding shares the right to call a special meeting, a move that enhances shareholder engagement and potential for activism. The second amendment allows for the exculpation of executive officers under new Delaware law provisions, which can be seen as a measure to protect leadership from certain liabilities. The filing also confirms the election of directors, the advisory approval of executive compensation, and the ratification of the independent registered public accounting firm, Ernst & Young LLP. All proposed amendments and routine matters were approved by stockholders, and these changes have become effective upon filing with the Secretary of State of the State of Delaware on May 8, 2024. The Board also approved a corresponding amendment to the Company's By-laws to support the special meeting provision.

May 9, 20248-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (May 2, 2024)

Moderna, Inc. filed an 8-K on May 2, 2024, primarily to announce its first-quarter 2024 financial results. The filing incorporates by reference a press release detailing these results, providing investors with an update on the company's financial performance. Key information regarding revenue, expenses, and profitability for the quarter ended March 31, 2024, is available through the furnished press release. While the 8-K itself is a procedural filing, the accompanying press release contains the substantive financial data. Investors should refer to Exhibit 99.1 for specific figures and commentary on Moderna's operational and financial condition during the first quarter. This includes any updates on product sales, research and development activities, and overall financial health as presented by the company.

May 2, 20248-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Feb 22, 2024)

Moderna, Inc. (MRNA) has filed an 8-K report on February 22, 2024, primarily to furnish its fourth quarter and full-year 2023 financial results as announced via press release. The key takeaway for investors is that the company has provided an update on its financial performance, although the detailed financial figures are contained within the furnished press release (Exhibit 99.1) and not directly enumerated within the 8-K's text itself. Investors should refer to the press release for specific revenue, profit, and cash flow details for the periods ending December 31, 2023. This filing serves as the official record of the press release's dissemination, assuring investors that the information presented by Moderna regarding its financial condition and operational results has been formally communicated. While the 8-K itself is a brief document, it directs stakeholders to the comprehensive unaudited financial results and management's discussion and analysis provided in the press release, which is crucial for evaluating Moderna's current financial health and future prospects.

Feb 22, 20248-K
Earnings & ResultsRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Jan 8, 2024)

Moderna, Inc. (MRNA) filed an 8-K on January 8, 2024, providing preliminary, unaudited financial updates for the fiscal year ended December 31, 2023, during its presentation at the J.P. Morgan Healthcare Conference. The company announced approximately $6.7 billion in product sales for the full year, primarily driven by its COVID-19 vaccine. This figure includes an estimated $0.6 billion in deferred revenue related to its GAVI collaboration. Furthermore, Moderna indicated a strong liquidity position, with cash, cash equivalents, and marketable securities expected to exceed $13 billion as of December 31, 2023. Investors should note that this information is preliminary and subject to audit, and the full audited financial statements may present changes. The filing serves as an early outlook on the company's performance and financial health heading into the new fiscal year.

Jan 8, 20248-K
Leadership Changes

Moderna, Inc. 8-K Report, Executive Changes (Dec 12, 2023)

Moderna, Inc. announced a significant change in its executive leadership with the departure of its Chief Commercial Officer, Arpa Garay, effective December 8, 2023. This departure follows a restructuring of the company's commercial organization, which will now be directly overseen by CEO Stéphane Bancel and President Stephen Hoge. Ms. Garay will remain with Moderna in an advisory capacity through June 2024 to ensure a smooth transition. Investors should note the financial implications of Ms. Garay's departure. She is eligible for severance benefits under the company's Executive Severance Plan, including twelve months of salary ($850,000), a target bonus for the year of departure ($765,000), and 12 months of COBRA coverage. Additionally, 15% of her unvested time-based equity awards will accelerate, and she will have an extended period to exercise vested stock options. Ms. Garay will not be eligible for new equity awards or a 2024 bonus beyond the severance package.

Dec 12, 20238-K
Regulation FD

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Nov 6, 2023)

Moderna, Inc. (MRNA) filed an 8-K on November 6, 2023, primarily to disclose the cancellation of a pre-arranged trading plan by its Chief Commercial Officer, Arpa Garay. This plan, known as the Garay 10b5-1 Plan, was established on August 24, 2023, with the intent to comply with Rule 10b5-1(c) for planned future stock sales. The cancellation occurred on November 6, 2023, subsequent to the company's Q3 2023 earnings release. Importantly, no shares were actually sold, and no options were exercised under this plan before its termination. The sales were scheduled to commence no earlier than November 27, 2023. This disclosure is important for investors to understand executive trading activities and the absence of any actual stock sales under the specific plan that was cancelled. The filing also includes standard Regulation FD disclosure language.

Nov 6, 20238-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Nov 2, 2023)

Moderna, Inc. (MRNA) filed an 8-K on November 2, 2023, primarily to report its financial results for the third quarter ended September 30, 2023. The company announced its Q3 2023 financial performance via a press release, which is furnished as an exhibit to this filing. Investors should note that this information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act, meaning it doesn't carry the same legal liabilities. The key takeaway for investors from this filing is the need to review the accompanying press release for detailed financial performance, revenue figures, profitability, and any forward-looking guidance provided by the company.

Nov 2, 20238-K
Regulation FD

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Oct 16, 2023)

Moderna, Inc. (MRNA) issued a statement on October 16, 2023, to reaffirm its previously provided revenue guidance for its COVID-19 vaccine for the full year 2023, which ranges from $6 billion to $8 billion. The company acknowledges the inherent uncertainty in projecting U.S. vaccination rates and stated that performance would fall in the lower half of the range if approximately 50 million doses are administered, and the upper half if approximately 100 million doses are administered. Moderna indicated that it is too early to definitively forecast the market size and expects to have better visibility into U.S. vaccination trends after observing data through October 2023. Investors can expect a further update on this matter during Moderna's earnings call scheduled for November 2, 2023. The company reiterated its forward-looking statements and cautioned that actual results could differ due to various risks and uncertainties.

Oct 16, 20238-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Sep 11, 2023)

Moderna, Inc. (MRNA) announced a significant strategic collaboration with Immatics N.V. on September 11, 2023, aimed at developing novel therapies for cancer patients with high unmet medical needs. This partnership leverages Moderna's mRNA platform with Immatics' expertise in T cell receptor (TCR) T cell therapies, signaling a strong commitment to advancing oncology treatments. Investors should view this as a strategic move to diversify Moderna's pipeline and tap into the promising field of immuno-oncology, potentially opening new revenue streams and enhancing long-term growth prospects.

Sep 11, 20238-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Aug 3, 2023)

Moderna, Inc. (MRNA) announced its financial results for the second quarter ended June 30, 2023, via a press release furnished on August 3, 2023. The report primarily serves to disclose these quarterly results. Investors should note that the information provided is furnished and not deemed 'filed' under the Securities Exchange Act, meaning it does not carry the same regulatory implications as a fully filed report but is crucial for understanding the company's recent performance. The key takeaway for investors is the release of Q2 2023 financial performance data. While the 8-K itself is a procedural filing to attach the press release, the press release (Exhibit 99.1) contains the operational and financial details that investors will scrutinize. This includes revenue, expenses, profitability, and any forward-looking statements or strategic updates provided by the company regarding its pipeline and business outlook.

Aug 3, 20238-K
Shareholder Matters

Moderna, Inc. 8-K Report, Shareholder Vote Results (May 5, 2023)

Moderna, Inc. (MRNA) filed an 8-K on May 5, 2023, detailing the results of its 2023 Annual Meeting of Stockholders held on May 3, 2023. The filing confirms the election of three Class II directors: Stephen Berenson, Sandra Horning, M.D., and Paul Sagan, all for three-year terms. Additionally, stockholders approved, on a non-binding advisory basis, the compensation of the company's named executive officers and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023. The meeting also saw a shareholder proposal requesting a report on the feasibility of transferring intellectual property. This proposal was not approved by the majority of the votes cast. Overall, the results indicate strong support for the company's board of directors, executive compensation practices, and auditor selection, while a shareholder-initiated proposal did not gain majority approval.

May 5, 20238-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (May 4, 2023)

Moderna, Inc. reported its first-quarter 2023 financial results via a press release filed on May 4, 2023. The primary focus of this filing is the dissemination of these Q1 2023 results, which are crucial for investors to assess the company's ongoing performance beyond its COVID-19 vaccine revenue. While the filing itself does not contain extensive new operational details, it directs investors to the press release (Exhibit 99.1) for the specific financial figures and management commentary. Investors should carefully review the furnished press release for details on revenue, earnings per share, cash position, and any updates regarding the company's product pipeline and commercialization strategies. The furnished information offers insights into Moderna's ability to navigate the evolving vaccine market and leverage its mRNA technology platform for future growth opportunities. It's important to note that the information is furnished, not filed, meaning it doesn't carry the same legal implications as a fully filed document under Section 18 of the Exchange Act.

May 4, 20238-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Feb 23, 2023)

Moderna, Inc. (MRNA) filed an 8-K on February 23, 2023, primarily to report its fourth quarter and full-year 2022 financial results via an attached press release. This filing provides investors with key financial performance metrics and operational updates for the period ending December 31, 2022. The information presented in this 8-K is furnished and not deemed 'filed' under the Securities Exchange Act of 1934, meaning it does not carry the same level of liability as a fully filed document. Investors should review the press release (Exhibit 99.1) for the detailed financial figures and business commentary, which will inform their assessment of the company's current financial standing and future outlook.

Feb 23, 20238-K
Earnings & ResultsRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Jan 9, 2023)

Moderna, Inc. filed an 8-K on January 9, 2023, providing preliminary unaudited financial results for the fiscal year ended December 31, 2022. The company announced robust product sales of approximately $18.4 billion, primarily driven by its COVID-19 vaccine. This strong revenue performance is a key takeaway for investors, demonstrating the continued commercial success of Moderna's flagship product. In addition to significant sales, Moderna reported research and development expenses of approximately $3.3 billion, highlighting its ongoing commitment to innovation and pipeline development. The company also ended the year with a strong liquidity position, expecting over $18 billion in cash, cash equivalents, and marketable securities. Investors should note that these figures are preliminary and unaudited, with final audited results to be released later.

Jan 9, 20238-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Jan 3, 2023)

Moderna, Inc. (MRNA) filed an 8-K on January 3, 2023, primarily to disclose a letter sent to its shareholders. This letter, attached as Exhibit 99.1, is the core of the filing and serves as a communication vehicle for the company to share its perspectives and updates directly with its investors. While the filing itself is brief and contains limited new operational or financial data, the shareholder letter is expected to contain crucial information regarding the company's recent performance, strategic direction, and outlook. Investors should carefully review the content of this letter for insights into Moderna's business, particularly its progress in vaccine development and commercialization, and any forward-looking statements.

Jan 3, 20238-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (Dec 13, 2022)

Moderna, Inc. (MRNA) announced a significant clinical trial milestone on December 13, 2022, via an 8-K filing. The company, in collaboration with Merck, reported that their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, successfully met the primary efficacy endpoint in the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial. This positive outcome represents a crucial step forward for the potential treatment of melanoma, particularly in combination with Merck's blockbuster immunotherapy drug, KEYTRUDA. The success of this personalized cancer vaccine, which aims to train the immune system to attack cancer cells based on an individual's tumor mutations, is a strong indicator of the potential for mRNA technology beyond infectious diseases. Investors will be closely watching for further developments, including the progression to Phase 3 trials and eventual regulatory submissions, as this could represent a significant new therapeutic avenue and revenue stream for Moderna in the oncology space.

Dec 13, 20228-K
Exhibits & Filings

Moderna, Inc. 8-K Report, Exhibit Filing (Nov 3, 2022)

Moderna, Inc. filed an 8-K on November 3, 2022, to furnish a press release detailing its financial results for the third quarter ended September 30, 2022. While the filing itself is procedural and incorporates the press release by reference, the core investor information lies within that press release. Investors should refer to the press release for specific financial metrics, operational updates, and forward-looking statements from Moderna regarding their performance and business outlook. This 8-K serves as the formal notification of the release of this crucial financial data.

Nov 3, 20228-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Sep 29, 2022)

Moderna, Inc. announced significant leadership changes in its operational and strategic functions through an 8-K filing on September 29, 2022. Juan Andres, previously Chief Technical Operations and Quality Officer, will transition to a new role as President, Strategic Partnerships and Enterprise Expansion, effective January 1, 2023. This move signals a strategic focus on expanding the company's organizational capabilities to support its developing pipeline. To fill the vacated operational role, Moderna has appointed Dr. Jerh Collins as the new Chief Technical Operations and Quality Officer, effective January 1, 2023. Dr. Collins brings extensive pharmaceutical production and manufacturing experience, having spent nearly 30 years at Novartis in senior leadership positions. These appointments are intended to strengthen Moderna's operational execution and strategic growth initiatives.

Sep 29, 20228-K
Leadership ChangesRegulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Executive Changes (Aug 17, 2022)

Moderna, Inc. (MRNA) announced a significant leadership change in its finance department via an 8-K filing on August 17, 2022. James Mock has been appointed as the new Chief Financial Officer (CFO), effective September 6, 2022. Mr. Mock brings extensive financial experience, most recently serving as CFO of PerkinElmer, Inc., and prior to that, nearly two decades at General Electric Company (GE), where he held various financial oversight roles. This transition involves the retirement of the current CFO, David Meline, who will remain with the company as a consultant to ensure a smooth handover. The company has outlined a comprehensive compensation package for Mr. Mock, including a substantial base salary, annual bonus potential, a significant signing bonus, and a notable new hire equity award valued at $6,000,000, subject to a four-year vesting period. This strategic appointment and compensation structure signal Moderna's commitment to strengthening its financial leadership as it continues to navigate its growth phase and commercialization efforts. Investors will be watching for continued financial discipline and strategic execution under Mr. Mock's leadership.

Aug 17, 20228-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (Aug 3, 2022)

Moderna, Inc. reported its second quarter 2022 financial results on August 3, 2022. The key takeaway for investors is the company's continued strong revenue performance, primarily driven by its COVID-19 vaccine sales. This filing provides a snapshot of the company's financial health and operational progress during the period, offering insights into sales trends and the underlying drivers of its financial condition. Investors should review the furnished press release for detailed financial figures and management commentary.

Aug 3, 20228-K/A
Leadership ChangesExhibits & Filings

Moderna, Inc. 8-K/A Report, Executive Changes (Jun 1, 2022)

Moderna, Inc. (MRNA) filed an 8-K/A amendment on June 1, 2022, to provide updated details regarding the agreement with its Chief Financial Officer, David Meline. The amendment clarifies that Mr. Meline will continue as CFO until December 31, 2022, or an earlier date when his successor begins. This transition includes a retirement date and an agreement for him to provide strategic consulting services to the company through March 2, 2026. The agreement outlines the compensation and equity vesting terms for Mr. Meline during and after his tenure as CFO. This includes continued vesting of current equity awards and specific provisions for bonus awards and stock option exercisability post-employment. Investors should note the extended consulting period and the specific conditions tied to equity vesting and option exercise, as these impact the company's long-term engagement with a key executive.

Jun 1, 20228-K
Regulation FDExhibits & Filings

Moderna, Inc. 8-K Report, Regulation FD Disclosure (May 24, 2022)

Moderna, Inc. (MRNA) filed an 8-K on May 24, 2022, primarily to disclose changes to CEO Stephane Bancel's personal stock trading plan under Rule 10b5-1. The key update is Mr. Bancel's decision to exercise a significant stock option granted in 2013, which is set to expire in August 2023. Mr. Bancel plans to exercise his option to acquire 4,587,155 shares at a nominal price of $0.99 per share, with exercises occurring weekly on Wednesdays and Thursdays starting May 25, 2022. Notably, he intends to contribute all after-tax proceeds from this exercise to charitable causes. This marks his first exercise of granted stock options. Investors should note that this disclosure is made under Regulation FD and is not considered 'filed' for certain liability purposes.

May 24, 20228-K/A
Leadership ChangesExhibits & Filings

Moderna, Inc. 8-K/A Report, Executive Changes (May 13, 2022)

Moderna, Inc. (MRNA) filed an amendment to its Form 8-K on May 13, 2022, to provide further details regarding the departure of its Chief Financial Officer, Jorge Gomez, which originally occurred on May 10, 2022. While Mr. Gomez was initially set to receive standard severance benefits, including 12 months of salary and COBRA coverage, the amended filing clarifies the terms of an Executive Separation Agreement and Release. This agreement introduces a clawback provision that allows Moderna to terminate or seek repayment of severance benefits if Mr. Gomez is found to have engaged in wrongdoing or faces penalties related to an internal investigation by Dentsply Sirona or the SEC. This addition is significant for investors as it introduces a contingency to the executive's separation package tied to potential past conduct. The company also entered into this agreement in consideration for a general release of claims from Mr. Gomez.

May 13, 20228-K
Leadership Changes

Moderna, Inc. 8-K Report, Executive Changes (May 11, 2022)

Moderna, Inc. announced a significant change in its Chief Financial Officer role through an 8-K filing on May 11, 2022. Jorge Gomez, the former CFO, departed the company, effective immediately. His departure is notable given its timing with the public disclosure of an internal investigation into financial reporting matters at his former employer, Dentsply Sirona Inc. While Gomez will receive severance benefits including 12 months of salary and COBRA coverage, he will forfeit certain previously disclosed benefits like his signing bonus and equity awards. In response to this unexpected vacancy, Moderna has appointed David Meline, who recently retired from the CFO position, to continue serving in the role effective May 11, 2022. Meline's compensation package remains largely consistent with his previous role, including a $700,000 annual salary and target annual incentive. Importantly, the Compensation Committee has approved continued eligibility for vesting of his 2022 equity awards and an extended exercise period for vested stock options, reflecting his continued critical role in the company's financial operations.

May 11, 20228-K
Earnings & ResultsExhibits & Filings

Moderna, Inc. 8-K Report, Financial Results (May 4, 2022)

Moderna, Inc. (MRNA) filed an 8-K on May 4, 2022, primarily to furnish a press release detailing its first-quarter financial results for the period ended March 31, 2022. The filing itself does not contain new substantive financial data but directs investors to the accompanying press release for these details. Investors should review Exhibit 99.1 for the specific financial performance, operational updates, and forward-looking statements released by Moderna. This 8-K serves as the official notification of the earnings release. While the information is furnished and not formally "filed" under certain sections of the Exchange Act, it represents the company's official communication of its quarterly performance. Key metrics such as revenue, net income, earnings per share, and any commentary on product sales (particularly COVID-19 vaccine sales) and pipeline developments would be found within the press release.

May 4, 2022
Page 1 of 3